证券日报网讯 1月20日，健尔康在互动平台回答投资者提问时表示，公司一直有出口欧盟业务，公司欧 盟出口业务主要为向欧盟客户直接出口和通过第三方贸易商销往欧盟，目前没有在欧盟国家设立子公司 进行销售的情况。 （文章来源：证券日报） ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

中信建投证券股份有限公司 关于健尔康医疗科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中信建投证券股份有限公司(以下简称"中信建投证券"或"保荐机构") 作 为健尔康医疗科技股份有限公司(以下简称"健尔康"或"公司")持续督导工作 的保荐机构,根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市 规则》《上海证券交易所上市公司自律监管指引第 1 号—规范运作》《上市公司募 集资金监管规则》等相关法规和规范性文件的要求,对健尔康使用部分闲置募集资 金进行现金管理的事项进行了审慎核查,并出具核查意见如下: 一、募集资金基本情况 根据中国证监会出具的《关于同意健尔康医疗科技股份有限公司首次公开发 行股票注册的批复》(证监许可[2024]808 号),同意公司首次公开发行股票的注册 申请,并经上海证券交易所同意,公司于 2024年 10 月 25 日首次向社会公开发行 人民币普通股(A 股)股票 3.000万股,每股发行价格为人民币 14.65元,募集资 金总额为人民币 439,500,000.00 元，扣除各项发行费用后募集资金净额为人民币 385.764.383.84 元。 以上募集资 ...

(一)交易目的 外汇远期结售汇是经中国人民银行批准的外汇避险金融产品。其交易原理是, 公司与银行等金融机构签订远期外汇合约,约定将来办理结售汇的外汇币种、金额、 汇率和期限,在交割日按照该远期结售汇合约约定的币种、金额、汇率办理结售汇 业务。公司所有拟开展的远期结售汇业务都是与日常经营紧密联系,以真实的出口 业务为依据，以规避和防范汇率风险为目的。 目前公司销售包括境内销售和境外销售两部分。公司境外采购销售的外汇收 付金额较大,外汇汇率波动对公司经营成果可能产生影响。为减少汇率波动带来 的风险,公司拟开展远期结售汇业务，降低汇率波动对公司经营业绩的影响。 中信建投证券股份有限公司(以下简称"中信建投证券"或"保荐机构")作 为健尔康医疗科技股份有限公司(以下简称"健尔康"或"公司")持续督导工作 的保荐机构,根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市 规则》《上海证券交易所上市公司自律监管指引第1号—规范运作》等相关法规和 规范性文件的要求,对健尔康开展远期结售汇业务的事项进行了审慎核查,并出具 核查意见如下: 一、交易情况概述 (二)交易金额 根据实际业务需要,公司拟开展金额不超过 6,0 ...

中信建投证券股份有限公司 关于健尔康医疗科技股份有限公司 2026年度日常关联交易预计的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作 为健尔康医疗科技股份有限公司（以下简称"健尔康"或"公司"）持续督导工作 的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市 规则》《上海证券交易所上市公司自律监管指引第 5 号—交易与关联交易》等相关 法规和规范性文件的要求，对健尔康 2026 年度日常关联交易预计事项进行了审慎 核查，并出具核查意见如下： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于 2025 年 12 月 18 日召开第二届董事会独立董事 2025 年第二次专门会 议，审议通过了《关于公司〈2026 年度日常关联交易预计〉的议案》，此议案获 得全体独立董事一致表决通过。独立董事认为公司 2025 年已发生的日常关联交 易和 2026 年度日常关联交易预计符合公司日常经营需要，交易定价符合市场定 价原则，不存在损害公司利益及全体股东特别是中小股东利益的情形，不会对公 司的生产经营产生不利影响，不会对关联方形成依赖，因此同意将该议 ...

为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》要求，积极 响应上海证券交易所《关于开展沪市公司"提质增效重回报"专项行动的倡议》， 健尔康医疗科技股份有限公司（以下简称"公司"）结合自身实际经营情况、发展 战略及财务状况，基于对未来持续稳定发展的信心和对公司价值的认可，制定了 健尔康医疗科技股份有限公司 2026 年度"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603205 证券简称：健尔康 公告编号：2025-040 《2026 年度"提质增效重回报"行动方案》（以下简称"行动方案"），旨在持续优 化经营效率、完善公司治理、强化投资者回报，不断增强核心竞争力，推动公司 高质量发展与投资价值提升，切实保护投资者尤其是中小投资者的合法权益。本 次行动方案已于 2025年 12 月 29 日经公司第二届董事会第十六次会议审议通过， 具体内容如下： 二、坚持规范运作，提升公司治理水平 公司严格遵循《公司法》《证券法》《上海证券交易所股票上市规则》等法 律法规、规范性文件及《公 ...

根据实际业务需要，公司用于开展远期结售汇业务在手合约的最高余额 为 6,000 万美元。 本交易已经公司第二届董事会审计委员会第十一次会议和第二届董事会 第十六次会议审议通过，无需提交公司股东会审议。 相关风险提示：开展远期结售汇业务可能面临汇率波动风险、内部控制 风险、客户违约风险等，敬请广大投资者注意投资风险。 一、交易情况概述 （一）交易目的 证券代码：603205 证券简称：健尔康 公告编号：2025-039 健尔康医疗科技股份有限公司 关于开展远期结售汇业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 外汇远期结售汇是经中国人民银行批准的外汇避险金融产品。其交易原理是， 公司与银行等金融机构签订远期外汇合约，约定将来办理结售汇的外汇币种、金 额、汇率和期限，在交割日按照该远期结售汇合约约定的币种、金额、汇率办理 结售汇业务。公司所有拟开展的远期结售汇业务都是与日常经营紧密联系，以真 实的出口业务为依据，以规避和防范汇率风险为目的。 本次交易的资金来源为自有资金，不涉及募集资金或银行信贷资金。 ...

证券代码：603205 证券简称：健尔康 公告编号：2025-038 健尔康医疗科技股份有限公司 关于2026年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据《上海证券交易所股票上市规则》《上海证券交易所上市公司自律 监管指引第 5 号——交易与关联交易》等有关规定，公司本次日常关联交易预计 事项无需提交股东会审议。 公司本次预计日常关联交易不会对关联方形成依赖，不影响公司的独立 性，不会对公司的持续经营能力、盈利能力及资产状况造成重大影响。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于 2025 年 12 月 18 日召开第二届董事会独立董事 2025 年第二次专门会 议，审议通过了《关于公司〈2026 年度日常关联交易预计〉的议案》，此议案 获得全体独立董事一致表决通过。独立董事认为公司 2025 年已发生的日常关联 交易和 2026 年度日常关联交易预计符合公司日常经营需要，交易定价符合市场 定价原则，不存在损害公司利益及全体股东特别是中小股东利益的情 ...

证券代码：603205 证券简称：健尔康 公告编号：2025-037 健尔康医疗科技股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 投资种类：安全性高、流动性好、低风险的理财产品。 投资金额：不超过 45,000（单日最高余额，含本数）万元人民币。 履行的审议程序：健尔康医疗科技股份有限公司（以下简称"公司"） 于 2025 年 12 月 19 日召开第二届董事会审计委员会第十一次会议，于 2025 年 12 月 29 日召开第二届董事会第十六次会议，审议通过了《关于使用闲置自有资 金进行现金管理的议案》，该议案无需提交公司股东会审议。 特别风险提示：公司拟使用暂时闲置自有资金购买的理财产品为安全性 高、流动性好的理财产品，属于低风险投资品种，但金融市场受宏观经济的影响 较大，敬请广大投资者谨慎决策，注意防范投资风险。 一、投资情况概述 （一）投资目的 为提高自有资金使用效率和收益，在做好日常资金调配、保证正常经营所需 资金不受影响的基础上，公司拟使用部分闲置自有资金进行现 ...

证券代码：603205 证券简称：健尔康 公告编号：2025-036 健尔康医疗科技股份有限公司 ●特别风险提示：尽管公司本次拟使用暂时闲置募集资金进行现金管理 用于购买安全性高、流动性好的满足保本要求的投资产品（包括但不限于协 定存款、定期存款、大额存单、保本型收益凭证等），但金融市场受宏观经 济影响较大，不排除该项投资受到市场波动影响的风险。敬请广大投资者注 意投资风险。 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意健尔康医疗科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2024〕808号），并经上海 证券交易所同意，公司本次首次公开发行人民币普通股（A股）股票（以下简 称"本次发行"）3,000万股，每股发行价格为人民币14.65元，募集资金总 额为人民币439,500,000元，扣除各项发行费用后募集资金净额为人民币 385,764,383.84元，以上募集资金已经天衡会计师事务所（特殊普通合伙） 于2024年10月31日出具的天衡验字（2024）00096号《健尔康医疗科技股份有 限公司验资报告》审验确认。 公司已根据相关法律法规、规范性文件的规定与保荐人及存放募集资 ...